Yantai Lannacheng Biotech Co., Ltd. was established in early 2021, with its headquarters in Yantai, China, and a subsidiary in Singapore. Founded by Dongcheng Pharmaceutical Group, a leading enterprise with significant influence in China’s nuclear medicine sector, Lannacheng is dedicated to the research, development, and registration of first-in-class innovative radiopharmaceuticals integrating diagnosis and therapy. The company is developing various theranostic radiopharmaceutical pipelines with strong translational potential, serving as a core part of Dongcheng’s nuclear medicine ecosystem.

In 2023, Lannacheng opened a 6,500+ m² integrated R&D facility supporting every stage of radiopharmaceutical discovery—from lead compound screening and targeted synthesis to radiolabeling, preclinical testing, and molecular imaging. The site features a comprehensive translational medicine infrastructure and rigorous quality systems, forming a core platform for drug screening and translational medicine. Together with a state-of-the-art formulation plant coming online, Lannacheng is creating a seamless path from research to manufacturing, accelerating the translation of innovation into clinical practice.

Starting at the microscopic level and advancing to the clinic, Lannacheng harnesses innovation to make precision medicine accessible to more patients, with a broad pipeline covering PSMA, FAP, integrin αvβ3, and multiple novel early-stage targets. This approach has produced a diverse, well-structured product portfolio.

The company’s theranostic radionuclide pipeline includes small molecules, peptides, and antibodies, with programs addressing prostate cancer, solid tumors, gliomas, and neuroendocrine tumors. Several promising new candidates have already been submitted for regulatory reviews in China and the United States, with global multicenter clinical trials underway. By 2025, Lannacheng had received 10+ IND approvals from regulatory agencies including China’s NMPA, the U.S. FDA, and Singapore’s HSA, with two programs advancing to Phase III trials.

Lannacheng views intellectual property as the foundation of innovation and the strategic cornerstone of global competitiveness. The company has systematically established a comprehensive IP network covering its core technologies and full product pipeline, with proactive patent strategies in major markets including China, North America, Europe, and Asia. This approach ensures robust protection of its innovations worldwide, supporting pipeline development, secure technology partnerships, and future commercialization, while enabling a smooth transition from laboratory research to market-ready products.

Following a global registration–oriented product development strategy and under the leadership of our Chief Medical Officer, Dr. Jingjing Zhang, Lannacheng has partnered with leading medical institutions worldwide, such as National University of Singapore, Melbourne Theranostic Innovation Centre (MTIC), University of Virginia, Peking Union Medical College Hospital, Fudan University Shanghai Cancer Center, Cancer Hospital of the Chinese Academy of Medical Sciences (Shenzhen Center), Ruijin Hospital (Shanghai Jiao Tong University, School of Medicine), Xijing Hospital (Air Force Medical University), Union Hospital (Tongji Medical College of HUST), First Affiliated Hospital of Xi’an Jiaotong University, Tongji Hospital (Tongji Medican College of HUST), and Beijing Hospital, among others.

Together, these collaborations have supported numerous sponsored clinical trials and investigator-initiated studies. Research findings have been published in top journals, such as Nature Reviews Bioengineering, Theranostics, Clinical Cancer Research, Journal of Nuclear Medicine, and European Journal of Nuclear Medicine and Molecular Imaging. Lannacheng’s innovations have also been actively presented at major conferences such as the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting and the European Association of Nuclear Medicine (EANM) Congress, receiving broad recognition and acclaims.

Powered by cutting-edge innovation and a strategy centered on multi-target approaches, diverse radionuclides, and integrated theranostics, Lannacheng is advancing nuclear medicine from diagnostic imaging to personalized precision therapy. The company aims to build a globally competitive radiopharmaceutical enterprise, establishing new paradigms for solid tumor treatment through precision theranostic systems and ensuring rapid translation of radiopharmaceuticals into clinical practice to benefit patients worldwide.